Redbiotec develops prophylactic vaccines, with a strong focus on HCMV (human cytomegalovirus).
After assembly of over 60 multi-protein variants and IP generation (2012) Redbiotec’s CMV program showed promising data in the recent initial in vivo study. Based on these results, Redbiotec will now enter into the next phase testing several combinations in order to evaluate the best lead by end of 2013.
Tackling Herpesviruses: data library
After Redbiotec’s achievements with the CMV vaccine development and based on the assembly power of its rePAX® platform, the company embarked on the creation of a Herpesvirus data library over the next years.
Redbiotec is convinced that this library will lead to the generation and optimization of Herpes vaccine candidates, and will eventually reveal potential causes of virus latency and help elucidate virus-triggered cancer mechanisms.